DK1341531T3 - Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese - Google Patents

Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese

Info

Publication number
DK1341531T3
DK1341531T3 DK01989070T DK01989070T DK1341531T3 DK 1341531 T3 DK1341531 T3 DK 1341531T3 DK 01989070 T DK01989070 T DK 01989070T DK 01989070 T DK01989070 T DK 01989070T DK 1341531 T3 DK1341531 T3 DK 1341531T3
Authority
DK
Denmark
Prior art keywords
inhibition
beta
synthesis
amyloid peptide
lactam compounds
Prior art date
Application number
DK01989070T
Other languages
Danish (da)
English (en)
Inventor
Varghese John
James Edmund Audia
Eugene D Thorsett
Lee H Latimer
Stacey Leigh Mcdaniel
Jeffrey Scott Nissen
Jay S Tung
Original Assignee
Lilly Co Eli
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Elan Pharm Inc filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1341531T3 publication Critical patent/DK1341531T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
DK01989070T 2000-11-17 2001-11-05 Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese DK1341531T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17
PCT/US2001/027799 WO2002047671A2 (fr) 2000-11-17 2001-11-05 Composé de lactam

Publications (1)

Publication Number Publication Date
DK1341531T3 true DK1341531T3 (da) 2007-05-14

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01989070T DK1341531T3 (da) 2000-11-17 2001-11-05 Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese

Country Status (34)

Country Link
US (1) US20050261495A1 (fr)
EP (1) EP1341531B1 (fr)
JP (1) JP4116437B2 (fr)
KR (1) KR100819679B1 (fr)
CN (1) CN1486184A (fr)
AR (1) AR035927A1 (fr)
AU (2) AU2002243192B2 (fr)
BR (1) BR0115427A (fr)
CA (1) CA2427227C (fr)
CY (1) CY1106366T1 (fr)
CZ (1) CZ20031351A3 (fr)
DE (1) DE60126132T2 (fr)
DK (1) DK1341531T3 (fr)
DZ (1) DZ3453A1 (fr)
EA (1) EA005954B1 (fr)
EC (1) ECSP034600A (fr)
ES (1) ES2278804T3 (fr)
HK (1) HK1059731A1 (fr)
HR (1) HRP20030383B1 (fr)
HU (1) HU228117B1 (fr)
IL (2) IL155960A0 (fr)
MX (1) MXPA03004292A (fr)
MY (1) MY134559A (fr)
NO (1) NO324324B1 (fr)
NZ (1) NZ525854A (fr)
PE (1) PE20020802A1 (fr)
PL (1) PL212199B1 (fr)
PT (1) PT1341531E (fr)
SI (1) SI1341531T1 (fr)
SK (1) SK288065B6 (fr)
TW (1) TWI305204B (fr)
UA (1) UA74849C2 (fr)
WO (1) WO2002047671A2 (fr)
ZA (1) ZA200303789B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
CA2603320A1 (fr) 2005-04-08 2006-10-19 Daiichi Sankyo Company, Limited Derive de pyridylmethylsulfone
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
WO2007088878A1 (fr) * 2006-01-31 2007-08-09 Api Corporation Procédé de production de benzazépinone
US20100204230A1 (en) 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
CL2008002060A1 (es) * 2007-07-16 2008-11-21 Wyeth Corp Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
BRPI0815135A2 (pt) 2007-08-14 2015-02-03 Lilly Co Eli Derivados de azepina como inibidores de gama secretase.
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
EP2291181B9 (fr) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Utilisation de la captodiamine pour le traitement des symptômes de la dépression
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CA2805265A1 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
CA2807307C (fr) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani)
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012040444A2 (fr) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Traitement de patients présentant un début de maladie d'alzheimer
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
EP3613418A1 (fr) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Procédés et compositions de modulation des niveaux d'hormones
WO2016069906A1 (fr) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne
CN109689071B (zh) 2016-05-16 2023-05-30 通用医疗公司 肺上皮工程中的人气道干细胞
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
EP3706747A4 (fr) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3743057A4 (fr) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary Traitement de la perte auditive
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
BR112022012032A2 (pt) 2019-12-17 2022-09-06 Merck Sharp & Dohme Llc Inibidores de prmt5
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
US20240208987A1 (en) 2022-10-25 2024-06-27 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (fr) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Charges utiles-lieur d'auristatine, compositions pharmaceutiques et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749658C (en) * 1996-12-23 2004-04-29 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
CA2324474A1 (fr) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide
EP1230220A1 (fr) * 1999-11-09 2002-08-14 Eli Lilly And Company COMPOSES CONTENANT DES $g(b)-ACIDES AMINES UTILES POUR INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE $g(b)-AMYLOIDE
ATE405577T1 (de) * 2000-11-17 2008-09-15 Lilly Co Eli Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition

Also Published As

Publication number Publication date
EP1341531B1 (fr) 2007-01-17
PE20020802A1 (es) 2002-09-10
US20050261495A1 (en) 2005-11-24
NO20032236L (no) 2003-07-10
CA2427227C (fr) 2010-08-17
AU4319202A (en) 2002-06-24
EA005954B1 (ru) 2005-08-25
PL362688A1 (en) 2004-11-02
KR20030051846A (ko) 2003-06-25
HRP20030383A2 (en) 2005-10-31
MY134559A (en) 2007-12-31
JP4116437B2 (ja) 2008-07-09
EP1341531A2 (fr) 2003-09-10
UA74849C2 (en) 2006-02-15
TWI305204B (en) 2009-01-11
CZ20031351A3 (cs) 2003-11-12
HRP20030383B1 (en) 2007-12-31
JP2004517090A (ja) 2004-06-10
CY1106366T1 (el) 2011-10-12
AR035927A1 (es) 2004-07-28
HUP0301842A2 (hu) 2003-09-29
NZ525854A (en) 2004-06-25
PL212199B1 (pl) 2012-08-31
NO20032236D0 (no) 2003-05-16
EA200300580A1 (ru) 2003-10-30
AU2002243192B2 (en) 2006-07-20
BR0115427A (pt) 2003-10-07
HK1059731A1 (en) 2004-07-16
PT1341531E (pt) 2007-04-30
ZA200303789B (en) 2004-08-16
KR100819679B1 (ko) 2008-04-04
ES2278804T3 (es) 2007-08-16
SK5592003A3 (en) 2003-12-02
WO2002047671A2 (fr) 2002-06-20
NO324324B1 (no) 2007-09-24
MXPA03004292A (es) 2004-02-12
HU228117B1 (en) 2012-11-28
IL155960A0 (en) 2003-12-23
SI1341531T1 (sl) 2007-06-30
CA2427227A1 (fr) 2002-06-20
IL155960A (en) 2009-06-15
SK288065B6 (sk) 2013-04-03
DE60126132D1 (de) 2007-03-08
DE60126132T2 (de) 2007-10-18
CN1486184A (zh) 2004-03-31
HUP0301842A3 (en) 2010-03-29
ECSP034600A (es) 2003-06-25
WO2002047671A3 (fr) 2003-03-06
DZ3453A1 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
DK1341531T3 (da) Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1181272T3 (da) Fremgangsmåde til fremstilling af rent citalopram
DK1181713T3 (da) Fremgangsmåde til fremstilling af rent citalopram
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK0824631T3 (da) Fremgangsmåde til inhibering af tilstopning af ledninger med gashydrater
AR028280A1 (es) Derivados de 2-amino-3-(alquil)-pirimidona
DK1044969T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser
DK0971920T3 (da) Forbindelser til inhibition af mavesyresekretion
EP1326647A4 (fr) Composes photosensibles destines a determiner instantanement la fonction d'un organe
AR027907A1 (es) Composicion de liberacion controlada
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
DK1204429T3 (da) Præparat til forsinket frigivelse af et peptid
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
DK1291356T3 (da) Fremgangsmåde til hurtig oplösningssyntese af peptider
ATE362919T1 (de) Lactamverbindungen
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1206462T3 (da) Hererocykliske forbindelser til inhibering af angiogenese
AR028070A1 (es) Sintesis de compuestos de ciclohexendimetanol o ciclohexandimetanol
DK1468996T3 (da) Indolderivater til behandling af CNS-sygdomme
DK1203000T3 (da) Fremgangsmåde til fremstilling af phosphonomethylglycin
DK1591122T3 (da) Fremgangsmåde til indgivelse af bisphosphonater